查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1596729

他汀类药物市场：按类型、药物类别、应用、最终用户划分 - 全球预测 2025-2030

Statins Market by Type (Natural Statins, Synthetic Statins), Drug Class (Atorvastatin, Fluvastatin, Lovastatin), Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年他汀类药物市场价值为316.1亿美元，预计2024年将达到333亿美元，复合年增长率为5.85%，预计2030年将达到470.8亿美元。

他汀类药物市场主要集中在抑制 HMG-CoA 还原酶的降胆固醇药物，该酶对于肝臟中胆固醇的产生至关重要。这些药物对于治疗高血脂症非常重要，旨在降低心血管风险，进而解决全球心臟病发病率上升的问题。他汀类药物市场的需求是由日益增长的公共卫生需求推动的，以控制心血管疾病，并广泛应用于高胆固醇水平患者的一级和二级预防。最终用途包括医院、诊所和家庭配方，是市场消费的主要动力。人口老化、久坐的生活方式以及人们对控制胆固醇水平、推动成长的重要性的认识不断提高，对市场动态产生了重大影响。此外，联合治疗和个人化医疗的出现正在为提高疗效和患者依从性创造机会。专利到期后学名药的激增也有望扩大市场准入。然而，副作用、药物交互作用以及他汀类药物以外的药物（如 PCSK9 抑制剂）的存在等限制带来了挑战。严格的法规环境和新兴替代疗法的竞争进一步阻碍了市场成长，这些替代疗法提供心血管益处且副作用更少。创新应着重于开发副作用最小的下一代他汀类药物，并实施数位健康解决方案来追踪患者的治疗结果和依从性。另一个有前景的部分是生物技术的进步，可以更好地标靶化影响血脂水平的脂蛋白因子，这可能会带来更好的治疗结果。了解市场需要认识到向预防性护理的转变以及消费者对心血管健康的日益增长的渴望，这正在推动公司利用创新的药物和输送系统。总之，儘管市场面临挑战，但策略创新和对监管环境的反应可以导致他汀类药物领域的业务显着成长。

主要市场统计
基准年[2023] 316.1亿美元
预测年份 [2024] 333亿美元
预测年份 [2030] 470.8亿美元
复合年增长率（%） 5.85%

市场动态：揭示快速发展的他汀类药物市场的关键市场洞察

他汀类药物市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 全球慢性病盛行率不断上升
    • 消费者对非处方药 (OTC) 的偏好日益增长
    • 由于消费者对保持健康生活方式的意识不断增强，对他汀类药物的需求增加
  • 市场限制因素
    • 新兴国家对替代药物的偏好日益增长
  • 市场机会
    • 开发新他汀类药物的研发活动不断成长
    • 对负担得起且有效的胆固醇维持解决方案的需求不断增长
  • 市场问题
    • 对他汀类药物副作用的担忧

波特五力：驾驭他汀类药物市场的策略工具

波特的五力架构是了解他汀类药物市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解他汀类药物市场的外部影响

外部宏观环境因素在塑造他汀类药物市场的表现动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析：了解他汀类药物市场的竞争格局

对他汀类药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：他汀类药物市场供应商的绩效评估

FPNV定位矩阵是评估他汀类药物市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製他汀类药物市场的成功之路

对他汀类药物市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争格局中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1. 市场渗透率：详细检视当前市场环境，主要企业的广泛资料，评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球慢性病发生率正在上升
      • 消费者对非处方药 (OTC) 的偏好日益增长
      • 消费者保持健康生活方式意识的增强正在推动他汀类药物的需求
    • 抑制因素
      • 新兴国家对替代医学的偏好日益增长
    • 机会
      • 扩大研发活动以开发新的他汀类药物
      • 对负担得起且有效的胆固醇维持解决方案的需求不断增长
    • 任务
      • 对他汀类药物副作用的担忧
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章他汀类药物市场：依类型

  • 介绍
  • 天然他汀类药物
  • 合成他汀类药物

第七章 他汀类药物市场：依药物类别

  • 介绍
  • Atorvastatin
  • 氟伐他汀
  • 洛伐他汀
  • 匹伐他汀
  • rosuvastatin
  • Simvastatin

第八章他汀类药物市场：依应用分类

  • 介绍
  • 发作
  • 心血管疾病
  • 糖尿病
  • 心臟病发作
  • 发炎
  • 文明病
  • 肥胖

第 9 章 他汀类药物市场：依最终使用者分类

  • 介绍
  • 诊所
  • 医院

第10章 美洲他汀类药物市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太他汀类药物市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章 欧洲、中东和非洲他汀类药物市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • AccuBioTech Co., Ltd.
  • Amgen Inc.
  • AstraZeneca PLC
  • Aurobindo Pharma Ltd.
  • Becton, Dickinson and Company
  • Biocon Limited
  • bioMerieux SA
  • Centrient Pharmaceuticals Netherlands BV
  • Concord BIoTech Limited
  • Danaher Corporation
  • DiaSorin SpA
  • F. Hoffman-La Roche AG
  • GlaxoSmithKline PLC
  • Grifols, SA
  • Merck & Co., Inc.
  • Nova Biomedical
  • Novartis AG
  • Pfizer Inc.
  • Quidel Corporation
  • Siemens AG
  • Terumo Corporation
  • Thermo Fisher Scientific, Inc.
  • Trinity BIoTech PLC
Product Code: MRR-FF012EDC38C1

The Statins Market was valued at USD 31.61 billion in 2023, expected to reach USD 33.30 billion in 2024, and is projected to grow at a CAGR of 5.85%, to USD 47.08 billion by 2030.

The statin market focuses primarily on cholesterol-lowering medications that impede the enzyme HMG-CoA reductase, pivotal in cholesterol production within the liver. These drugs are critical in treating hyperlipidemia, aiming at cardiovascular risk reduction, thereby addressing soaring global heart disease rates. The statin market's necessity stems from the growing public health demand to manage cardiovascular diseases, with broad applications in both primary and secondary prevention for patients exhibiting high cholesterol levels. End-use spans hospital settings, clinics, and household prescriptions, fueling significant market consumption. Market dynamics are heavily influenced by an aging population, sedentary lifestyles, and increasing awareness of the importance of managing cholesterol levels, driving growth. Additionally, opportunities are emerging from the advent of combination therapies and personalized medicine, which could enhance efficacy and patient adherence. A surge in generic drugs post-patent expiration is also expected to expand market accessibility. However, limitations such as adverse side effects, drug interactions, and the presence of non-statins like PCSK9 inhibitors pose challenges. Market growth is further impeded by stringent regulatory environments and competition from emerging alternative treatments that promise cardiovascular benefits with fewer side effects. For innovation, focus should be on developing next-generation statins with minimal side effects and incorporating digital health solutions to track patient outcomes and adherence. Other promising areas include biotechnological advancements allowing for more refined targeting of lipoprotein factors influencing blood lipid levels, potentially achieving superior therapeutic outcomes. Understanding the marketplace entails recognizing a shift towards preventative healthcare measures and growing consumer inclination for thorough cardiovascular health, presenting businesses with opportunities to harness innovative drugs and delivery systems. Conclusively, while the market faces challenges, strategic innovation and responsiveness to regulatory landscapes can yield considerable business growth in the statin domain.

KEY MARKET STATISTICS
Base Year [2023] USD 31.61 billion
Estimated Year [2024] USD 33.30 billion
Forecast Year [2030] USD 47.08 billion
CAGR (%) 5.85%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Statins Market

The Statins Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increase in the incidence of chronic diseases globally
    • Rising consumer preference for over-the-counter (OTC) drugs
    • Escalating demand for statins due to increasing consumer awareness about maintaining a healthy lifestyle
  • Market Restraints
    • Increasing preference for alternative medicines in emerging economies
  • Market Opportunities
    • Growth in R&D activities for newer statin development
    • Emerging demand for affordable and effective cholesterol-maintaining solutions
  • Market Challenges
    • Concerns associated with side-effects of statins

Porter's Five Forces: A Strategic Tool for Navigating the Statins Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Statins Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Statins Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Statins Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Statins Market

A detailed market share analysis in the Statins Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Statins Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Statins Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Statins Market

A strategic analysis of the Statins Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Statins Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AccuBioTech Co., Ltd., Amgen Inc., AstraZeneca PLC, Aurobindo Pharma Ltd., Becton, Dickinson and Company, Biocon Limited, bioMerieux S.A., Centrient Pharmaceuticals Netherlands B.V., Concord Biotech Limited, Danaher Corporation, DiaSorin S.p.A., F. Hoffman-La Roche AG, GlaxoSmithKline PLC, Grifols, S.A., Merck & Co., Inc., Nova Biomedical, Novartis AG, Pfizer Inc., Quidel Corporation, Siemens AG, Terumo Corporation, Thermo Fisher Scientific, Inc., and Trinity Biotech PLC.

Market Segmentation & Coverage

This research report categorizes the Statins Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Natural Statins and Synthetic Statins.
  • Based on Drug Class, market is studied across Atorvastatin, Fluvastatin, Lovastatin, Pitavastatin, Rosuvastatin, and Simvastatin.
  • Based on Application, market is studied across Attacks, Cardiovascular Diseases, Diabetes, Heart Strokes, Inflammation, Lifestyle Diseases, and Obesity.
  • Based on End-User, market is studied across Clinics and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in the incidence of chronic diseases globally
      • 5.1.1.2. Rising consumer preference for over-the-counter (OTC) drugs
      • 5.1.1.3. Escalating demand for statins due to increasing consumer awareness about maintaining a healthy lifestyle
    • 5.1.2. Restraints
      • 5.1.2.1. Increasing preference for alternative medicines in emerging economies
    • 5.1.3. Opportunities
      • 5.1.3.1. Growth in R&D activities for newer statin development
      • 5.1.3.2. Emerging demand for affordable and effective cholesterol-maintaining solutions
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with side-effects of statins
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Statins Market, by Type

  • 6.1. Introduction
  • 6.2. Natural Statins
  • 6.3. Synthetic Statins

7. Statins Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Atorvastatin
  • 7.3. Fluvastatin
  • 7.4. Lovastatin
  • 7.5. Pitavastatin
  • 7.6. Rosuvastatin
  • 7.7. Simvastatin

8. Statins Market, by Application

  • 8.1. Introduction
  • 8.2. Attacks
  • 8.3. Cardiovascular Diseases
  • 8.4. Diabetes
  • 8.5. Heart Strokes
  • 8.6. Inflammation
  • 8.7. Lifestyle Diseases
  • 8.8. Obesity

9. Statins Market, by End-User

  • 9.1. Introduction
  • 9.2. Clinics
  • 9.3. Hospitals

10. Americas Statins Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Statins Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Statins Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AccuBioTech Co., Ltd.
  • 3. Amgen Inc.
  • 4. AstraZeneca PLC
  • 5. Aurobindo Pharma Ltd.
  • 6. Becton, Dickinson and Company
  • 7. Biocon Limited
  • 8. bioMerieux S.A.
  • 9. Centrient Pharmaceuticals Netherlands B.V.
  • 10. Concord Biotech Limited
  • 11. Danaher Corporation
  • 12. DiaSorin S.p.A.
  • 13. F. Hoffman-La Roche AG
  • 14. GlaxoSmithKline PLC
  • 15. Grifols, S.A.
  • 16. Merck & Co., Inc.
  • 17. Nova Biomedical
  • 18. Novartis AG
  • 19. Pfizer Inc.
  • 20. Quidel Corporation
  • 21. Siemens AG
  • 22. Terumo Corporation
  • 23. Thermo Fisher Scientific, Inc.
  • 24. Trinity Biotech PLC

LIST OF FIGURES

  • FIGURE 1. STATINS MARKET RESEARCH PROCESS
  • FIGURE 2. STATINS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL STATINS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL STATINS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL STATINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL STATINS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL STATINS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL STATINS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL STATINS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL STATINS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL STATINS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL STATINS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL STATINS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS STATINS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS STATINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES STATINS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES STATINS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC STATINS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC STATINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA STATINS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA STATINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. STATINS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. STATINS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. STATINS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL STATINS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL STATINS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL STATINS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. STATINS MARKET DYNAMICS
  • TABLE 7. GLOBAL STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL STATINS MARKET SIZE, BY NATURAL STATINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL STATINS MARKET SIZE, BY SYNTHETIC STATINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL STATINS MARKET SIZE, BY ATORVASTATIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL STATINS MARKET SIZE, BY FLUVASTATIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL STATINS MARKET SIZE, BY LOVASTATIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL STATINS MARKET SIZE, BY PITAVASTATIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL STATINS MARKET SIZE, BY ROSUVASTATIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL STATINS MARKET SIZE, BY SIMVASTATIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL STATINS MARKET SIZE, BY ATTACKS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL STATINS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL STATINS MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL STATINS MARKET SIZE, BY HEART STROKES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL STATINS MARKET SIZE, BY INFLAMMATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL STATINS MARKET SIZE, BY LIFESTYLE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL STATINS MARKET SIZE, BY OBESITY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL STATINS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL STATINS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS STATINS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES STATINS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC STATINS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. INDIA STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. INDONESIA STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. INDONESIA STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. JAPAN STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. JAPAN STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. MALAYSIA STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. MALAYSIA STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. PHILIPPINES STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. SINGAPORE STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. SINGAPORE STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH KOREA STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. TAIWAN STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. TAIWAN STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. THAILAND STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. THAILAND STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 105. VIETNAM STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. VIETNAM STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA STATINS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 114. DENMARK STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. DENMARK STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. EGYPT STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. EGYPT STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 122. FINLAND STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. FINLAND STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. FRANCE STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. FRANCE STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. GERMANY STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. GERMANY STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. ISRAEL STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. ISRAEL STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 138. ITALY STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. ITALY STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. NETHERLANDS STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. NETHERLANDS STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 146. NIGERIA STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. NIGERIA STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 150. NORWAY STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 151. NORWAY STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 154. POLAND STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 155. POLAND STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 158. QATAR STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 159. QATAR STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 162. RUSSIA STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. RUSSIA STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 166. SAUDI ARABIA STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 167. SAUDI ARABIA STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH AFRICA STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH AFRICA STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 174. SPAIN STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 175. SPAIN STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 178. SWEDEN STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 179. SWEDEN STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 182. SWITZERLAND STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. SWITZERLAND STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 186. TURKEY STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 187. TURKEY STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED ARAB EMIRATES STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM STATINS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM STATINS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED KINGDOM STATINS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED KINGDOM STATINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 196. STATINS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 197. STATINS MARKET, FPNV POSITIONING MATRIX, 2023